Non-GAAP R&D expense in the third quarter of 2021 was 9% versus 9.2% in Q3 of 2020.
Non-GAAP SG&A in the third quarter of 2021 was 29.6% versus 29.4% in Q3 of 2020.
Full year non-GAAP gross margin is now projected to be between 57.5% and 57.8% versus prior guidance of 57% and 57.5%.
Excluding Process Media sales and the $32 million settlement for back royalties, the underlying Life Science business declined 2% on a currency-neutral basis versus Q3 of 2020 due to lower COVID-related sales.
We are now guiding full year 2021 non-GAAP currency-neutral revenue growth to be between 12% and 13% versus our prior guidance of 10% to 10.5%.
